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Objective To report complication rates following prolapse surgery
using polypropylene mesh inlay, polypropylene mesh kit,
biological collagen xenografts and native tissue repairs.
Design Secondary analysis of the PROSPECT randomised
controlled trial and cohort study.
Setting Thirty-five UK hospitals.
Population A total of 2632 women undergoing anterior and/or
posterior vaginal prolapse repair.
Methods Event rates were calculated for all complications.
Analysis was by treatment received.
Main outcome measures IUGA/ICS classification of complications
and validated patient reported outcome measures.
Results At baseline, 8.4% of women had ‘generic’ pain/discomfort;
at 2 years following surgery, there was an improvement in all four
groups; however, 3.0% of women developed de novo extreme
generic pain. At 24 months de novo vaginal tightness occurred in
1.6% of native tissue, 1.2% of biological xenograft, 0.3% of mesh
inlay and 3.6% of mesh kit. Severe dyspareunia occurred in
4.8% of native tissue, 4.2% of biological xenograft, 3.4% of
mesh inlay repairs and 13.0% of mesh kits. De novo severe
dyspareunia occurred in 3.5% of native tissue, 3.5% of
biological xenograft, 1.4% of mesh inlays and 4.8% of mesh kits.
Complications requiring re-admission to hospital, unrelated to
mesh, affected 1 in 24 women; the most common reasons for
re-admission were vaginal adhesions, urinary retention,
infection and constipation.
Conclusions This is the first study to address the complications of
vaginal mesh used for prolapse surgery alongside data from both
native tissue and biological xenograft. It demonstrates the
complexity of assessing pain and that all types of prolapse surgery
have low surgical morbidity and a low rate of severe
complications.
Keywords Cumberlege report, dyspareunia, IUGA/ICS
complications classification, pain, polypropylene mesh, prolapse,
surgery, surgical complications.
Tweetable abstract A prospective study of 2362 women
undergoing vaginal mesh, xenograft or native tissue repair found
low surgical morbidity and low rates of severe complications.
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Introduction
Transvaginal polypropylene mesh for pelvic organ prolapse
(POP) and stress urinary incontinence has been the subject
of much controversy with its use being suspended in some
countries as the result of complications,1 and several series
including the management of such complications have been
published.2,3
The evidence collected during the Cumberlege inquiry in
the UK4 has highlighted serious side effects of the use ofPROSPECT study group members are presented in Appendix A.
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mesh and short comings in medical practice. The report,
First do no harm, states that there is a risk of harm not
only from the primary surgical procedure but also from
subsequent mesh removal surgery.
Very few studies have compared the complications of
POP surgery using polypropylene mesh or biological xeno-
grafts compared with native tissue surgery.
PROSPECT, one of the largest multicentre comprehen-
sive cohort studies with an embedded randomised con-
trolled trial comparing native tissue, biological xenograft
and mesh for transvaginal repair of anterior and posterior
compartment pelvic organ prolapse, revealed no significant
differences in patient-reported outcomes at 2 years.5–7 Seri-
ous adverse effects, defined as causing death, requiring
admission to hospital or prolongation of existing hospital
admission, resulting in significant incapacity or disability,
or otherwise considered important by the investigator were
comparable across treatment groups.
To provide more detailed information about
mesh-related complications, especially pain, a secondary
analysis of the complete PROSPECT data set, both ran-
domised and those in the comprehensive cohort study, was
undertaken using the internationally recommended Inter-
national Urogynecological Association (IUGA)/Interna-
tional Continence Society (ICS) classification.8,9 This
provides information about the type of complication, the
anatomical site where it occurred, severity and the time of
onset. There is also a subclassification of pain severity,
from asymptomatic to unprovoked spontaneous pain.
Studies have shown that following instruction and training
there is good inter-observer reliability10 and others report
that this is a useful method for assessing the severity of
complications.2,3 Unlike PROSPECT, most studies have
been retrospective and have not included a control group
of women undergoing native tissue surgery.
Following the Cumberlege Report, the aim of this PRO-
SPECT secondary analysis is to provide more detailed
information, using validated patient-reported outcome
measures (PROMS) and a standardised complication classi-
fication system, to help in patient counselling.
Methods
Participants
All participants recruited into the PROSPECT study who
underwent a transvaginal anterior and/or posterior prolapse
operation (either primary or secondary repair) were included
in this secondary analysis. The study group included a lay
person who was involved in all aspects of the study, from
planning to reporting. Randomised and non-randomised
women having a PROSPECT study treatment for either a
primary repair or repeat procedure were included and the
operation could include concomitant uterine, vault or
continence surgery. Exclusion criteria were concomitant
abdominal surgery (continence procedures, hysterectomy,
uterine suspension or vault fixation) or upper compartment
prolapse only. All women provided written informed con-
sent to participate in the PROSPECT study.
Procedure
Participating surgeons used their usual surgical techniques for
native tissue repairs, polypropylene mesh inlay, biological
xenograft and mesh kits. The mesh was non-absorbable type
1 monofilament microporous polypropylene mesh, with or
without absorbable coating (‘hybrid mesh’). Mesh kits were
defined as those that used removable trocars to place the
mesh. Bespoke or pre-cut ‘armed’ mesh was classed as an
inlay if trocars were not used. The biological xenografts were
porcine acellular collagen matrix, porcine small intestine sub-
mucosa or bovine dermal grafts. Mesh inlays and biological
xenografts were inserted below the fascial layer if possible and
secured with peripheral sutures to the fascia or arcus tendi-
nous fascia pelvis (‘white line’) or the sacrospinous ligament.
Outcomes
Information regarding the surgical procedure and any com-
plications before discharge was collected directly from the
research team at each participating hospital. Information
on study-related adverse events, self-reported pain and
need for readmission/further treatment was collected by
participant-completed postal questionnaires at 6 months, 1
and 2 years after surgery. Reports from participants were
verified by the local research team where possible.
Generic pain/discomfort was recorded from the pain
questions within EQ-5D-3L, the questionnaire has three
responses for pain/discomfort (none, moderate or severe)11
Serious adverse events were subsequently defined using the
recommended IUGA/ICS classifications, including the sub-
classification for pain.8,9
There are currently no agreed Core Outcomes in
Women’s and Newborn Health (CROWN) for pelvic floor
dysfunction. A panel of validated core outcomes relevant to
women’s symptoms was completed by postal questionnaire.
These included the Pelvic Organ Prolapse Symptom Score
(POP-SS),12 prolapse-specific quality-of-life and generic
quality-of-life based on the EQ-5D-3L.11 Bladder, bowel
and sexual function were measured using validated or
adapted International Consultation on Incontinence Ques-
tionnaires (ICIQ).13 Several individual questions were
reported from these validated questionnaires.
Objective measurement of prolapse stage used the POP-Q
system14 at 1 year after surgery (randomised women only).
Statistical analysis
Analysis was carried out by treatment received according to
study treatment (native tissue repair, mesh inlay, biological
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xenograft, or mesh kit). Baseline characteristics and com-
plication rates are presented for each group and for all par-
ticipants combined. Clopper–Pearson exact 95% CI are
reported. Complication rates for each category presented
are calculated as the percentage of participants who experi-
enced one or more events in that category. Only observed
data are included in the analysis, e.g. de novo rates were
calculated only for participants with data collected at base-
line and at follow up. The analysis sought to describe com-
plications for different surgical procedures rather than to
examine any hypotheses and hence no inferential tests were
conducted to compare treatments. Analysis was conducted
using SAS v 9.4 (SAS Institute, Cary, NC, USA).
Results
The PROSPECT study operated on 2632 women included in
this analysis; 1712 had a native tissue repair, 482 received a
polypropylene mesh inlay, 360 a biological xenograft and 78
a mesh kit. The baseline characteristics by treatment received
are shown, for each group, in Table 1. Of note within the
randomised controlled trial section of PROSPECT biological
xenograft was not used for recurrent prolapse cases and
mesh kits were not used for primary cases.
Table 2 summarises the complications of prolapse surgery
and demonstrates that the perioperative safety of all types of
prolapse surgery is good. A bladder injury was sustained by
1 in 263 women (0.4%, 95% CI 0.2–0.7%) and bowel injury
by 1 in 526 (0.2%, 95% CI 0.1–0.4%, Table S1).
Excessive blood loss, clinically estimated as greater than
500 ml, was reported in 1 in 165 cases (0.6%, 95% CI 0.3–
1.0%); there were none in the mesh kit group.
Return to theatre within the first 72 hours occurred in 1
in 139 cases (0.7%, 95% CI 0.4–1.1%), the majority of
these were for haemorrhage.
Prolonged catheterisation (more than 10 days) occurred
in 3.9% (95% CI 3.2–4.7%) of all cases, although it was
more common in the mesh kit group.
At 24 months, de novo urinary incontinence, of any type,
occurred in approximately 1 in 16 of all cases (6.2%, 95%
CI 5.3–7.3%) with the exception of the mesh kit group, in
which it was 1 in 36 cases (2.8%, 95% CI 0.3–9.7%).
Postoperative vaginal adhesions were found in 1 in 60
women (1.7%, 95% CI 1.2–2.2%) and were most common
following a xenograft (1 in 30, 3.3%, 95% CI 1.7–5.8%).
Re-admission to hospital for complications of surgery
over the 2-year period, unrelated to mesh, was relatively
common affecting 1 in 24 women (4.3%, 95% CI 3.5–
5.1%); the most common reasons for re-admission were
for management of vaginal adhesions, urinary retention,
postoperative infection and constipation.
Despite the routine use of perioperative prophylactic
antibiotics, infection was not uncommon, affecting
approximately 1 in 40 women (2.4%, 95% CI 1.9–3.1%)
although severe infection associated with abscess was rare,
affecting fewer than 1 in 1000 women (0.1%, 95% CI 0.01–
0.3%). There was only one case of pulmonary embolism
reported following surgery.
In those who received mesh, surgical removal of mesh
occurred in 7.9% (95% CI 5.5–11.1%) of cases, although
the exact extent of removal was not recorded. Mesh expo-
sure was found in 12.0% of women; however, 64.2% of
these exposures were asymptomatic (Table S1).
The IUGA/ICS classification of complications is shown in
Table 3. The most severe injuries were in Category 7 ‘patient
compromise’, which is divided into three subcategories
(Table S1). Category 7A (bleeding complication including
haematoma) was common, 1 in 46 cases overall (2.2%, 95%
CI 1.6–2.8%). However, need for major resuscitation or
intensive care was uncommon, 1 in 239 cases (0.4%, 95% CI
0.2–0.7%) and there were no deaths (7C) related to surgery.
Overall repeat prolapse surgery in the first 2 years was
uncommon – only 0.3% (95% CI 0.1–0.7%) and all
occurred in the mesh inlay group.
Of note there was little difference in complication rates
including pain, between primary and secondary surgery for
standard native tissue repairs and mesh inlays (Table S2).
Table 4, Table S3 and the radar plots (Figure S1) pro-
vide further details of the pain associated with all types of
prolapse surgery.
Severe vaginal pain, before surgery, was reported by
3.4% (95% CI 2.7–4.2%) of women across all groups. The
incidence of pain in the mesh kit group at baseline was
lower than in other groups at 1.4% (95% CI 0.0–7.4%).
Severe dyspareunia, at baseline, was reported by 9.6%
(95% CI 8.0–11.4%) of women.
At 2 years following surgery, there was an overall
improvement in the rate of severe dyspareunia in all groups
expect those who had a mesh kit. In this group, there was
no change in the number of women who had severe dys-
pareunia. Vaginal pain also improved in all groups except
in women who had a mesh kit, although the numbers in
this group were low.
De novo vaginal tightness was more common after native
tissue repair or biological xenograft than after a mesh inlay.
At baseline, using EQ-5D-3L, 8.4% (95% CI 7.3–9.6%)
of women reported extreme pain or discomfort for any rea-
son; this was not necessarily related to prolapse. This was
found to have a sustained improvement after surgery across
all methods of surgery (Table 4). However, at 24 months,
extreme de novo generic pain developed in 3.0% (95% CI
2.3–3.8%) of women in all groups except the mesh kit
group, in which there were no cases.
Rates of pain related to prolapse surgery, assessed using
the IUGA/ICS classification, were low and results were sim-
ilar in each group (Table S2).
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Discussion
Main findings
Our study demonstrates the safety of both primary and
secondary prolapse surgery but highlights areas of morbid-
ity that are common, such as infection, urinary retention
and vaginal adhesions. These could be highlighted in the
patient information used in counselling before surgery and
management could be improved by using evidence-based
protocols.
One of the most common complications was vaginal
adhesions, occurring in 1 in 60 cases overall and 1 in 30
cases associated with a biological xenograft. Adhesions
might reduce the risk of recurrent prolapse but may
increase dyspareunia rates and may even result in women
no longer being able to have penetrative sexual intercourse
following their surgery. Further research should assess the
use of estrogen on the formation of adhesions or the use of
a vaginal insert to prevent adhesion formation.
Our study provides an important insight into the back-
ground incidence of concurrent pain with prolapse and the
risk of developing de novo pain or dyspareunia following
all types of prolapse surgery. It demonstrates the complex-
ity of assessing pain and the need for both comparisons to
baseline and other treatment options.
Strengths
The key strengths of the PROSPECT study are its size,
prospective data collection, inclusion of patient-reported
outcome measures and free-text questions, its generalisabil-
ity to current UK practice and the ability to describe com-
plications of native tissue, biological xenograft and mesh
repairs at 2 years. The inclusion of the large comprehensive
cohort increases the generalisability and allows for much
greater precision in the event rate estimates.
Complications may be under-reported in routine clinical
practice or registries. In our study, each hospital was asked
to report any serious adverse event that occurred during
the procedure to the point of discharge and the women
were asked to report serious adverse events in their postal
questionnaires, which were then confirmed with the hospi-
tal where possible; this dual method of reporting serious
adverse events reduced but did not eliminate the possibility
that complications could be under-reported.














Injury to organs n (%) 13 (0.5%) 10 (0.6%) 2 (0.4%) 1 (0.3%) 0 (0.0%)




n (%) 19 (0.7%) 11 (0.6%) 5 (1.0%) 2 (0.6%) 1 (1.3%)
Catheterisation
required >10 days
n (%) 103 (3.9%) 70 (4.1%) 14 (2.9%) 12 (3.3%) 7 (9.0%)
Complications within 24 months
Urinary retention n (%) 78 (3.0%) 53 (3.1%) 12 (2.5%) 9 (2.5%) 4 (5.1%)
Vaginal adhesions n (%) 44 (1.7%) 25 (1.5%) 6 (1.2%) 12 (3.3%) 1 (1.3%)
Resulting in
hospitalisation
n (%) 152 (5.8%) 70 (4.1%) 48 (10.0%) 29 (8.1%) 5 (6.4%)
Related to mesh n (%) 40 (1.5%) 2 (0.1%) 34 (7.1%) 1 (0.3%) 3 (3.8%)
Unrelated to mesh n (%) 112 (4.3%) 68 (4.0%) 14 (2.9%) 28 (7.8%) 2 (2.6%)
Patient compromise* n (%) 67 (2.5%) 39 (2.3%) 15 (3.1%) 10 (2.8%) 3 (3.8%)
Mesh complications** resulting in surgery within 24 months (from questionnaire data)
Surgical removal
of mesh
N n (%) 2074 38 (1.8%) 1329 2 (0.2%) 390 31 (7.9%) 290 0 (0.0%) 65 5 (7.7%)
Repeat prolapse
surgery
N n (%) 2075 7 (0.3%) 1329 0 (0.0%) 391 7 (1.8%) 290 0 (0.0%) 65 0 (0.0%)
De novo urinary incontinence (from questionnaire data)
At 12 months N n (%) 2404 151 (6.3%) 1548 95 (6.1%) 447 28 (6.3%) 336 24 (7.1%) 73 4 (5.5%)
At 24 months N n (%) 2387 149 (6.2%) 1542 94 (6.1%) 442 30 (6.8%) 331 23 (6.9%) 72 2 (2.8%)
*IUGA Classification 7 A, B and C (Although there were no deaths).
**Includes complications resulting from concomitant procedures in which mesh may have been used.
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Limitations
One possible limitation of the study is that randomised
women were only examined once in the postoperative per-
iod at 12 months, which skewed the time point data for
detection of asymptomatic mesh exposure. However, it
would be expected that if women were symptomatic, they
would have sought help.15
A limitation of this analysis is that any comparison between
treatment groups must be made with caution. Given the defi-
nition of the groups by treatment received (rather than by
randomised allocation), the combination of primary and sec-
ondary repairs and the inclusion of the non-randomised
cohort, comparisons could be subject to potentially significant
confounding For this reason, we have sought only to present
a descriptive summary of complication rates for each type of
surgery rather than to make formal comparisons between
treatments. A further statistical limitation arises from missing
data, which are quite plausibly not missing at random.
Although there was rigorous adherence to adverse event
reporting and high questionnaire response rates (91% at
1 year and 80% at 2 years), there remains a risk of a small
amount of bias in the results and the direction of this effect is
difficult to determine. However, sensitivity analyses under-
taken in the main trial under varying assumptions of missing-
ness did not indicate non-response bias.5
Different types of pain (generic, dyspareunia, vaginal)
were assessed using several measures, PROMs, EQ-5D-3L
and free-text communications from women. The IUGA/ICS
category time site (CTS) subclassification of provoked pain
(a–-e) was determined using women’s free-text responses,












1. Vaginal: no epithelial separation n (%) 178 (6.8%) 104 (6.1%) 30 (6.2%) 37 (10.3%) 7 (9.0%)
2. Vaginal: smaller, ≤1 cm exposure n (%) 49 (1.9%) 3 (0.2%) 39 (8.1%) 1 (0.3%) 6 (7.7%)
3. Vaginal: larger, >1 cm exposure,
or any extrusion
n (%) 24 (0.9%) 2 (0.1%) 21 (4.4%) 0 (0.0%) 1 (1.3%)
4. Urinary tract: compromise
or perforation
n (%) 84 (3.2%) 57 (3.3%) 13 (2.7%) 10 (2.8%) 4 (5.1%)
5. Rectal or bowel: compromise
or perforation
n (%) 5 (0.2%) 1 (0.1%) 3 (0.6%) 1 (0.3%) 0 (0.0%)
6. Skin or musculoskeletal:
complications
n (%) 15 (0.6%) 8 (0.5%) 6 (1.2%) 1 (0.3%) 0 (0.0%)
7. Patient: compromise* n (%) 67 (2.5%) 39 (2.3%) 15 (3.1%) 10 (2.8%) 3 (3.8%)
Time (clinically diagnosed)
T1: Intraoperative to 48 hours n (%) 9 (0.3%) 7 (0.4%) 2 (0.4%) 0 (0.0%) 0 (0.0%)
T2: 48 hours to 2 months n (%) 7 (0.3%) 6 (0.4%) 0 (0.0%) 1 (0.3%) 0 (0.0%)
T3: 2–12 months n (%) 316 (12.0%) 172 (10.0%) 85 (17.6%) 46 (12.8%) 13 (16.7%)
T4: Over 12 months n (%) 63 (2.4%) 18 (1.1%) 30 (6.2%) 11 (3.1%) 4 (5.1%)
Site
S1: Vaginal: area of suture line n (%) 104 (4.0%) 34 (2.0%) 48 (10.0%) 19 (5.3%) 3 (3.8%)
S2: Vaginal: away from suture line n (%) 168 (6.4%) 88 (5.1%) 43 (8.9%) 25 (6.9%) 12 (15.4%)
S3: Adjoining viscus/trocar
passage**
n (%) 98 (3.7%) 66 (3.9%) 17 (3.5%) 11 (3.1%) 4 (5.1%)
S4: Other skin or
musculoskeletal site
n (%) 17 (0.6%) 10 (0.6%) 6 (1.2%) 1 (0.3%) 0 (0.0%)
S5: Intra-abdominal n (%) 17 (0.6%) 12 (0.7%) 3 (0.6%) 2 (0.6%) 0 (0.0%)
Pain
a: Asymptomatic or no pain n (%) 144 (5.5%) 72 (4.2%) 46 (9.5%) 21 (5.8%) 5 (6.4%)
b: Provoked pain only n (%) 8 (0.3%) 3 (0.2%) 2 (0.4%) 2 (0.6%) 1 (1.3%)
c: Pain during sexual intercourse n (%) 33 (1.3%) 20 (1.2%) 8 (1.7%) 5 (1.4%) 0 (0.0%)
d: Pain during physical activities n (%) 4 (0.2%) 3 (0.2%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
e: Spontaneous pain n (%) 65 (2.5%) 34 (2.0%) 22 (4.6%) 7 (1.9%) 2 (2.6%)
Unspecified n (%) 131 (5.0%) 67 (3.9%) 35 (7.3%) 21 (5.8%) 8 (10.3%)
*Patient compromise 7A: Bleeding complication including haematoma; 7B: Major degree of resuscitation or intensive care; 7C: Mortality.
**Adjoining viscus (e.g. bladder or bowel) for native tissue repairs and trocar passage for mesh repairs.
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so of the 241 women who complained of pain, only 46%
could be categorised a to e.
Even in a study the size of PROSPECT, of 2632 women,
serious rare complications might not be detected, which
highlights the need for registries, such as the Medicines
and Health Regulatory Agency, to which serious complica-
tions can be reported.
There was a relatively small number of surgeries performed
with polypropylene mesh kits (n = 78; 3% of overall sample).
These were mainly performed in cases of recurrent prolapse
hence the numbers were much lower than other methods of
surgery. Data from kits and inlays were presented separately
because we believe that they represent significantly different
operations. Inlays and kits were investigated in separate trials
within PROSPECT for primary and secondary prolapse
repairs, respectively. The study was designed to have suffi-
cient statistical power in the primary trial, whereas the smal-
ler trial of recurrent prolapse was exploratory.
Prolapse is a long-term condition and there is a need to
report complications for longer than 12 months. The
follow-up data from our study were collected for 2 years
and ongoing 6 years follow-up data are being collected.
Interpretation in light of other evidence
The Cumberlege report called for further studies to
inform women and clinicians of the risk of complications
of mesh. Our study gives this and also provides the
important contextual comparison to the risks of native
tissue surgery. The pragmatic study design enables clini-
cians to use reliable data to counsel women about all the
risks of prolapse surgery and also to benchmark their
practice.
Initial studies of complications of transvaginal
polypropylene mesh surgery for POP focused on mesh per-
foration, exposure and extrusion rates (‘erosion’).16 These
can cause severe morbidity; however, they are relatively rare
but in the absence of a registry it is impossible to accu-
rately calculate their true incidence.
The British Society of Urogynaecology (BSUG) surgical
audit database, has been used for 13 years and contains
large amounts of data; nonetheless, not all procedures are
included because reporting is not mandatory and is
restricted to members of BSUG. Therefore, the recommen-
dation by Cumberlege of mandatory reporting to a national
registry is welcomed.
Table 4. Rates of self-reported pain
All procedures Native tissue repair Mesh inlay Biological xenograft Mesh kit
Generic pain (‘extreme pain or discomfort’)
Baseline N n (%) 2400 201 (8.4%) 1541 133 (8.6%) 454 32 (7.0%) 332 28 (8.4%) 73 8 (11.0%)
6 months N n (%) 2325 116 (5.0%) 1494 82 (5.5%) 430 16 (3.7%) 328 14 (4.3%) 73 4 (5.5%)
De novo N n (%) 2166 55 (2.5%) 1382 40 (2.9%) 408 8 (2.0%) 306 5 (1.6%) 70 2 (2.9%)
12 months N n (%) 2370 125 (5.3%) 1520 84 (5.5%) 443 22 (5.0%) 334 16 (4.8%) 73 3 (4.1%)
De novo N n (%) 2201 57 (2.6%) 1396 38 (2.7%) 422 11 (2.6%) 313 5 (1.6%) 70 3 (4.3%)
24 months N n (%) 2070 112 (5.4%) 1324 78 (5.9%) 388 18 (4.6%) 292 14 (4.8%) 66 2 (3.0%)
De novo N n (%) 1921 57 (3.0%) 1221 40 (3.3%) 365 9 (2.5%) 273 8 (2.9%) 62 0 (0.0%)
Vaginal pain (‘all of the time’)
Baseline N n (%) 2380 81 (3.4%) 1536 52 (3.4%) 442 14 (3.2%) 329 14 (4.3%) 73 1 (1.4%)
12 months N n (%) 2143 26 (1.2%) 1364 17 (1.2%) 401 2 (0.5%) 311 5 (1.6%) 67 2 (3.0%)
De novo N n (%) 1982 14 (0.7%) 1256 12 (1.0%) 375 1 (0.3%) 287 0 (0.0%) 64 1 (1.6%)
24 months N n (%) 2050 22 (1.1%) 1317 13 (1.0%) 385 4 (1.0%) 284 2 (0.7%) 64 3 (4.7%)
De novo N n (%) 1886 14 (0.7%) 1211 8 (0.7%) 352 3 (0.9%) 263 0 (0.0%) 60 3 (5.0%)
Vaginal tightness (‘all of the time’)
Baseline N n (%) 2273 13 (0.6%) 1462 11 (0.8%) 425 1 (0.2%) 319 1 (0.3%) 67 0 (0.0%)
12 months N n (%) 2096 37 (1.8%) 1340 24 (1.8%) 387 5 (1.3%) 303 6 (2.0%) 66 2 (3.0%)
De novo N n (%) 1868 31 (1.7%) 1184 19 (1.6%) 351 4 (1.1%) 273 6 (2.2%) 60 2 (3.3%)
24 months N n (%) 1999 27 (1.4%) 1283 20 (1.6%) 376 2 (0.5%) 280 3 (1.1%) 60 2 (3.3%)
De novo N n (%) 1777 24 (1.4%) 1134 18 (1.6%) 332 1 (0.3%) 256 3 (1.2%) 55 2 (3.6%)
Dyspareunia (‘a lot’)
Baseline N n (%) 1211 116 (9.6%) 765 77 (10.1%) 229 18 (7.9%) 183 18 (9.8%) 34 3 (8.8%)
12 months N n (%) 1059 58 (5.5%) 672 36 (5.4%) 201 14 (7.0%) 161 6 (3.7%) 25 2 (8.0%)
De novo N n (%) 822 31 (3.8%) 515 18 (3.5%) 154 7 (4.5%) 132 5 (3.8%) 21 1 (4.8%)
24 months N n (%) 948 44 (4.6%) 602 29 (4.8%) 179 6 (3.4%) 144 6 (4.2%) 23 3 (13.0%)
De novo N n (%) 738 23 (3.1%) 462 16 (3.5%) 140 2 (1.4%) 115 4 (3.5%) 21 1 (4.8%)
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The quality of evidence concerning the risk of complica-
tions following polypropylene mesh surgery for both incon-
tinence and prolapse remains poor. For example, research
which does not have a comparative standard ‘native tissue’
group can present a biased evidence base whereas studies
that only present data using hospital episode statistics data
are limited by the type of clinical information available and
potential coding errors.17 Another historical problem has
been an over-reliance on case series conducted in one expert
unit, which are later found to not be generalisable.18,19
The Cumberlege report called for greater knowledge of
the incidence and the reasons for of loss of sex life, chronic
pain, infection, difficulty voiding, de novo urinary inconti-
nence, haemorrhage and damage to surrounding organs
following mesh surgery and autoimmune diseases or psy-
chiatric injury. This study provides most of this informa-
tion not only for mesh surgery but importantly for all
types of prolapse surgery (with the exception of autoim-
mune diseases or psychiatric injury).
This is the first study to report complications following
mesh, biological xenograft and native tissue surgery using
the IUGA/ICS classification code. Most reports in the liter-
ature are case series of mesh complications that report no
denominator and no comparative group. More recent con-
cerns have been raised about the incidence of pain and dys-
pareunia, both of which can have a delayed onset.3 Miklos
et al.3 reported a cases series of 250 women. They found
that 48.4% had a chief complaint of pain, 43.2% had vagi-
nal exposure and only 4.8% had experienced perforation of
an organ. Over 85% were reported more than 12 months
after the index operation.
Miklos et al.3 stressed the importance of pain as a
symptom. They felt that significantly more women were
bothered by pain rather than mesh exposure. However,
they did not report a control group and the denominator
for these complication cases was unknown. Our study has
demonstrated the complexity of assessing pain and the
need to consider de novo pain. It suggests that severe de
novo generic pain can occur in up to 3.0% of women
24 months after surgery but that it can occur after all
types of prolapse surgery. The incidence of pain recorded
from patient free-text questionnaires, converted to the
CTS classification was higher than that recorded using
PROMs; this is possibly because severity was not consid-
ered. Also, the IUGA/ICS classification does not consider
de novo pain.
One of the most difficult problems that clinicians cur-
rently face is counselling women about the risks and bene-
fits of mesh removal surgery for pain, in the absence of
exposure or extrusion (‘erosion’)/perforation. Our study
does not help to answer this important question, but it
demonstrates similar rates of severe de novo pain and dys-
pareunia after each type of prolapse surgery.
Conclusion
This is the first study to prospectively address the compli-
cations of vaginal polypropylene mesh used for prolapse
surgery alongside comparable data from both biological
collagen xenographs and ‘standard’ native tissue repairs. It
demonstrates that all types of prolapse surgery have low
surgical morbidity and a low rate of severe complications.
However, there are some women who will experience sev-
ere de novo pain, dyspareunia and other life-changing
morbidities after all types of prolapse surgery. Our results
should help clinicians when counselling women who are
contemplating a surgical treatment for their prolapse. Fur-
ther research is required to standardise outcomes and to
determine the best methods to treat complications.
Disclosure of interests
Dr. Reid has nothing to disclose. Completed disclosure of
interests form available to view online as supporting infor-
mation.
Contribution to authorship
FR, AE, SB and RF wrote the first draft of the manuscript
which was reviewed, modified and approved by all
authors. AE analysed the data, which were interpreted by
all other authors. SB managed the PROSPECT study with
support, input and oversight from FR and RF. All the
authors vouch for the accuracy and completeness of the
data reported.
Details of ethics approval
PROSPECT was approved by the North of Scotland
Research Ethics Committee (NOSRES) on 7 July 2009
(REC reference number 09/SO802/56).
Funding
The project was funded by the National Institute for Health
Research Health Technology Assessment Programme (Pro-
ject Number 07/60/18). The Health Services Research Unit
is funded by the Chief Scientist Office of the Scottish
Government Health and Social Care Directorates.
Acknowledgements
The authors wish to thank the women who participated in
the PROSPECT study. We also thank Margaret MacNeil
for her secretarial support and data management, the pro-
gramming team in CHaRT and the staff at the recruitment
sites who facilitated the recruitment, treatment and follow
up of study participants.6
Disclaimer
The views and opinions expressed herein are those of the
authors and do not necessarily reflect those of the Health
2187ª 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
The complications of mesh, biological collagen xenograft and native tissue surgery for pelvic organ prolapse
Technology Assessment Programme, the National Institute
of Health Research, the National Health Service or the
Department of Health.
Data availability statement
Author elects to not share data.
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the
article.
Figure S1. Radar Plots of IUGA/ICS classification of
complications related directly to female pelvic reconstruc-
tive surgery.
Table S1. Complication rates by IUGA classification cat-
egory and subcategory.
Table S2. IUGA classification of complications related to
primary and secondary repairs.
Table S3. Complication rates by IUGA classification cat-
egory and pain subclassification.&
References
1 NHS Improvement and NHS England. Vaginal Mesh: High Vigilance
Restriction Period: Immediate Action Required, All Cases Should be
Postponed If it is Clinically Safe to Do So. London, UK: NHS
Improvement and NHS England; 2018 [https://i.emlfiles4.com/cmpd
oc/9/7/2/8/1/1/files/47633_mesh-letter-to-acute-ceos-and-mds.pdf].
Accessed 5 August 2020.
2 Firoozi F, Ingber MS, Moore CK, Vasavada SP, Rackley RR, Goldman
HB. Purely transvaginal/perineal management of complications from
commercial prolapse kits using a new prostheses/grafts complication
classification system. J Urol 2012;187:1674–9.
3 Miklos JR, Chinthakanan O, Moore RD, Mitchell GK, Favors S, Karp
DR, et al. The IUGA/ICS classification of synthetic mesh
complications in female pelvic floor reconstructive surgery: a
multicenter study. Int Urogynecol J 2016;27:933–8.
4 First Do No Harm. The Report of the Independent Medicines and
Medical Devices Safety Review. UK: APS Group; 2020 [https://www.
immdsreview.org.uk/downloads/IMMDSReview_Web.pdf]. Accessed
5 August 2020.
5 Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman
R, et al. Clinical effectiveness and cost-effectiveness of surgical
options for the management of anterior and/or posterior vaginal
wall prolapse: Two randomised controlled trials within a
comprehensive cohort study - results from the PROSPECT study.
Health Technol Assess 2016;20:1–452.
6 Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman
R, et al. Mesh, graft, or standard repair for women having primary
transvaginal anterior or posterior compartment prolapse surgery:
two parallel-group, multicentre, randomised, controlled trials
(PROSPECT). Lancet 2017;28:381–92.
7 Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman R,
et al. Mesh inlay, mesh kit or native tissue repair for women having
repeat anterior or posterior prolapse surgery: Randomised controlled
trial (PROSPECT). BJOG: Int J Obstetr Gynaecol 2020;127:1002–13.
8 Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J,
et al. An international urogynecological association (IUGA)/
international continence society (ICS) joint terminology and
classification of the complications related directly to the insertion of
prostheses (meshes, implants, tapes) & grafts in female pelvic floor
surgery. Int Urogynecol J 2011;22:3–15.
9 Haylen BT, Freeman RM, Lee J, Swift SE, Cosson M, Deprest J, et al.
An international urogynecological association (IUGA)/international
continence society (ICS) joint terminology and classification of the
complications related to native tissue female pelvic floor surgery. Int
Urogynecol J 2012;23:515–26.
10 Haylen BT, Lee J, Maher C, Deprest J, Freeman R. Optimizing study
design for interobserver reliability: IUGA-ICS classification of
complications of prostheses and graft insertion. Int Urogynecol J
2014;25:751–4.
11 Dolan P. Modeling valuations for EuroQol health states. Med Care
1997;35:1095–108.
12 Hagen S, Glazener C, Sinclair L, Stark D, Bugge C. Psychometric
properties of the pelvic organ prolapse symptom score. BJOG
2009;116:25–31.
13 Abrams P, Avery K, Gardener N, Donovan J. The international
consultation on incontinence modular questionnaire: w***ww.iciq.
net. J Urol 2006;175:1063–6.
14 Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JOL, Klarskov
P, et al. The standardization of terminology of female pelvic organ
prolapse and pelvic floor dysfunction. Obstet Gynecol 1996;175:10–
7.
15 Bateman AG, Neilens H, Gericke CA, George J, Freeman RM. Is
there a need for postoperative follow-up after routine
urogynaecological procedures? Patients will self-present if they have
problems. Int Urogynecol J 2014;25:381–6.
16 Yamada BS, Govier FE, Stefanovic KB, Kobashi KC. Vesicovaginal
fistula and mesh erosion after perigee (transobturator polypropylene
mesh anterior repair). Urology 2006;68:1121.e5–e7.
17 Keltie K, Elneil S, Monga A, Patrick H, Powell J, Campbell B, et al.
Complications following vaginal mesh procedures for stress urinary
incontinence: an 8 year study of 92,246 women. Sci Rep
2017;7:12015.
18 Raz S, Sussman EM, Erickson DB, Bregg KJ, Nitti VW. The raz
bladder neck suspension: results in 206 patients. J Urol
1992;148:845–50.
19 Kelly H, Dumm WM. Urinary incontinence in women, without
manifest injury to the bladder. Surg Gynecol Obstet 1914;18:444.
Appendix A
PROSPECT study group: CMA Glazener: Centre for
Healthcare Randomised Trial, Health Services Research
Unit, University of Aberdeen, Aberdeen, UK; C Hemming:
Department of Obstetrics and Gynaecology, Aberdeen
Royal Infirmary, Aberdeen, UK; KG Cooper: Department
of Obstetrics and Gynaecology, Aberdeen Royal Infirmary,
Aberdeen, UK, ARB Smith: The Warrell Unit, Saint Mary’s
Hospital, Manchester University NHS Foundation Trust,
Manchester Academic Health Science Centre, Hathersage
Road, Manchester M13 9WL, UK and Institute of Human
Development, Faculty of Medical & Human Sciences,
University of Manchester, Manchester Academic Health
Science Centre, Oxford Road, Manchester M13 9PL, UK; S
Hagen: NMAHP Research Unit, Glasgow Caledonian
2188 ª 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Reid et al.
University, Glasgow, UK; I Montgomery: Centre for
Healthcare Randomised Trial, Health Services Research
Unit, University of Aberdeen, Aberdeen, UK; M Kilonzo:
Health Economics Research Unit, University of Aberdeen,
Aberdeen, UK and Usher Institute of Population Health
Sciences & Informatics, University of Edinburgh, Edin-
burgh, UK, D Boyers: Health Economics Research Unit,
University of Aberdeen, Aberdeen, UK and Usher Institute
of Population Health Sciences & Informatics, University of
Edinburgh, Edinburgh, UK; A McDonald: Centre for
Healthcare Randomised Trial, Health Services Research
Unit, University of Aberdeen, Aberdeen, UK; G McPher-
son: Centre for Healthcare Randomised Trial, Health Ser-
vices Research Unit, University of Aberdeen, Aberdeen,
UK; G MacLennan: Centre for Healthcare Randomised
Trial, Health Services Research Unit, University of Aberd-
een, Aberdeen, UK, J Norrie: Health Economics Research
Unit, University of Aberdeen, Aberdeen, UK and Usher
Institute of Population Health Sciences & Informatics,
University of Edinburgh, Edinburgh, UK.
2189ª 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
The complications of mesh, biological collagen xenograft and native tissue surgery for pelvic organ prolapse
